Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3822166 | La Presse Médicale | 2014 | 14 Pages |
SummaryAutoimmune neutropenia (AIN) is a rare entity caused by antibodies directed against neutrophil-specific antigens. It includes primary and secondary autoimmune neutropenia. Acute autoimmune neutropenia can be related to drug-induced mechanism or viral infections. Chronic autoimmune neutropenias occur in the context of autoimmune diseases, hematological malignancies, such as large granular lymphocyte leukemia, primary immune deficiency syndromes or solid tumors. The therapeutic management depends on the etiology. Granulocyte growth factor is the main therapeutic option, raising the question of their long-term utilization safety. Corticosteroids or immunosuppressive therapy are indicated in infection-related AIN or in case of symptomatic autoimmune disease or LGL leukemia.In this issueImmune thrombocytopenic purpura: major progress in knowledge of the pathophysiology and the therapeutic strategy, but still a lot of issuesBertrand GodeauPathogenesis of immune thrombocytopeniaDouglas B Cines, Adam Cuker, John W SempleITP and international guidelines, what do we know, what do we need?Francesco Rodeghiero, Marco RuggeriThrombopietic agents: There is still much to learnJames B. Bussel, Madhavi LakkarajaIs B-cell depletion still a good strategy for treating immune thrombocytopenia?Bertrand Godeau, Roberto StasiNovel treatments for immune thrombocytopeniaAndrew Shih, Ishac Nazi, John G. Kelton, Donald M. ArnoldWarm autoimmune hemolytic anemia: advances in pathophysiology and treatmentMarc MichelAutoimmune neutropeniaAline Moignet, Thierry Lamy